Literature DB >> 27066521

Clinical Response to IncobotulinumtoxinA, after Demonstrated Loss of Clinical Response to OnabotulinumtoxinA and RimabotulininumtoxinB in a Patient with Musician's Dystonia.

Vesper Fe Marie Llaneza Ramos1, Barbara I Karp2, Codrin Lungu3, Katharine Alter4, Mark Hallett1.   

Abstract

Botulinum toxin is a mainstay therapy for dystonia. Formulations available are three types of botulinumtoxinA and one type of botulinumtoxinB.1 Antibodies can develop against the toxin, leading to treatment failure. IncobotulinumtoxinA (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt, Germany) is differentiated from other types of botulinumtoxinA preparations by being free from complexing proteins, speculated to make the product less antigenic.2.

Entities:  

Keywords:  incobotulinumtoxinA; musician’s dystonia; onabotulinumtoxinA; rimabotulinumtoxinB

Year:  2014        PMID： 27066521      PMCID： PMC4822507          DOI： 10.1002/mdc3.12094

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


  10 in total

1.  Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.

Authors:  Ravi Jandhyala
Journal:  J Drugs Dermatol       Date:  2012-06       Impact factor: 2.114

2.  Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.

Authors:  Petr Kaňovský; Jaroslaw Slawek; Zoltan Denes; Thomas Platz; Georg Comes; Susanne Grafe; Irena Pulte
Journal:  J Rehabil Med       Date:  2011-05       Impact factor: 2.912

3.  Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.

Authors:  C Sankhla; J Jankovic; D Duane
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

4.  Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.

Authors:  Codrin Lungu; Barbara I Karp; Katharine Alter; Regina Zolbrod; Mark Hallett
Journal:  Mov Disord       Date:  2011-02-01       Impact factor: 10.338

Review 5.  Clinical utility of different botulinum neurotoxin preparations.

Authors:  Steven B Abrams; Mark Hallett
Journal:  Toxicon       Date:  2013-01-30       Impact factor: 3.033

6.  Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report.

Authors:  Andrea Santamato; Maurizio Ranieri; Francesco Panza; Vincenza Frisardi; Maria Francesca Micello; Serena Filoni; Pietro Fiore
Journal:  J Rehabil Med       Date:  2012-09       Impact factor: 2.912

7.  Long-term outcome of focal dystonia in string instrumentalists.

Authors:  Stephan Schuele; Richard J Lederman
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

8.  Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.

Authors:  P A Hanna; J Jankovic
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

9.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

Review 10.  A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses.

Authors:  James P Bonaparte; David Ellis; Jason G Quinn; Mohammed T Ansari; Jessica Rabski; Shaun J Kilty
Journal:  Syst Rev       Date:  2013-06-13
  10 in total
  1 in total

1.  Neurotoxin Impurities: A Review of Threats to Efficacy.

Authors:  Je-Young Park; Owen Sunga; Rungsima Wanitphakdeedecha; Jürgen Frevert
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.